In vivo experiments were used to evaluate the effects of a JNK inhibitor, an IL-8 neutralizing antibody, and a VEGFA neutralizing antibody on tumor proliferation and the tumor microenvironment. The gene discussed is CXCL8; the disease is neoplasm.